Crispr Therapeutics AG vs State Street PDR S&P Retail ETF — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while State Street PDR S&P Retail ETF trades at $89.65. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | XRT | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $92.35 |
52-Week Low | $44.34 | $77.28 |
Enterprise Value | $3.65B | — |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →